CRAFA
PEPTIDE & COMPOUND ANALYSIS

Independent Peptide & Research-Compound Testing
14 Mill Lane, Cambridge, United Kingdom

CERTIFICATE OF ANALYSIS

Certificate of Analysis (COA)

No. CRF-2026-2067
Issued: 2026-10-14

PRODUCT IDENTIFICATION

PRODUCT		SKU / INTERNAL CODE
Ipamorelin 5 mg		CRF-2026-2067
PRESENTATION		BATCH NUMBER
Lyophilised powder, 5 mg vial		LOT-2610-2067
CLIENT	SAMPLE RECEIVED	ANALYSIS DATE
veltispeptides.mx	2026-10-09	2026-10-12
PRODUCTION DATE	ISSUED	EXPIRY / RETEST
2026-10-07	2026-10-14	2028-10-14

MOLECULAR FORMULA
C38H49N9O5

MOLECULAR WEIGHT	CAS NUMBER
711.85	170851-70-4

ANALYTICAL METHOD

PANEL
SILVER - HPLC-UV + LC-MS/MS + ICP-MS (Pb/As/Cd/Hg) + LAL endotoxin

METHOD
RP-HPLC-UV 214 nm · LC-MS/MS ESI Q-TOF · ICP-MS · LAL kinetic chromogenic (USP <85>)

INSTRUMENT
Waters ACQUITY · Agilent 7900 ICP-MS · Charles River Endosafe nexgen-PTS

Column: C18 4.6×150mm | Temperature: 35°C | Mobile phase: 0.1% TFA H2O / ACN | Flow: 1.0 mL/min | Retention time: 7.4 min

1. PURITY & ASSAY - RP-HPLC-UV (214 nm)

Test	Specification	Result	Status
HPLC Purity	≥98.0%	99.7%	PASS
Quantity	95.0-105.0%	5.02 mg (100.4%)	PASS

2. LC-MS/MS STRUCTURAL CONFIRMATION

Test	Reported data	Status
Theoretical [M+H]+	712.9 | Observed: 713.0 | Δ +0.10 Da	PASS
Sequence Coverage (MS/MS)	≥95% | 100% (Aib-His-D-2-Nal-D-Phe-Lys-NH2)	PASS
Key fragments	b2 314.2 · b4 597.3 · y3 340.2 · y5 551.3	PASS
Modifications	D-2-Nal4 and D-Phe5 confirmed by chiral retention shift; C-terminal amide confirmed (-0.98 Da)	PASS

3. HEAVY METALS - ICP-MS (USP <232>/<233>)

Test	Specification	Result	Status
Pb		<0.05 µg/g	PASS
As		<0.10 µg/g	PASS
Cd		<0.02 µg/g	PASS
Hg		<0.01 µg/g	PASS

4. ENDOTOXIN - LAL kinetic chromogenic (USP <85>)

Test	Reported data	Status
Result	<1.0 EU/mg limit | 0.19 EU/mg | PPC recovery 93%	PASS

FINAL BATCH RESULT

PASS - Conforms to specifications

ANALYST NOTES

Pentapeptide, highly selective GH secretagogue (no ACTH/cortisol elevation). No D-His epimerisation detected.

crafa

CRAFA